The Immunotherapies Congress

Recent advances in cancer immunotherapy have turned researcher's attentions to new therapeutic strategies focused on improved specificity, control of key checkpoints in immune response, the identification of new biomarkers and novel ways of combining therapies for maximum effect. The two-conference Immunotherapies Congress offers an exciting opportunity to learn how these strategies are being translated into the next generation of cancer immunotherapeutic drug products.

The first meeting, Emerging Cancer Immunotherapies and Vaccines, will examine new targets and strategies in this space, and explore how the lessons learned from early cancer vaccines are driving development of longer-lasting and more potent immune responses. A second conference, Immunomodulatory Therapeutic Antibodies for Cancer showcases the exciting wave of checkpoint blockades such as anti-PD-1 and antii-CTLA-4 now in clinical development – and explores considerations of trial design, drug safety and biomarker discovery that will influence their application in patients.